Literature DB >> 23499203

Treatment outcome and prognostic factors of adult glioblastoma multiforme.

Niloofar Ahmadloo1, Amir-Abbas Kani, Mohammad Mohammadianpanah, Hamid Nasrolahi, Shapour Omidvari, Ahmad Mosalaei, Mansour Ansari.   

Abstract

INTRODUCTION: This study aimed to report the characteristics, prognostic factors and treatment outcome of 223 patients with glioblastoma multiforme (GBM). SUBJECTS AND
METHOD: This retrospective study was carried out by reviewing the medical records of 223 adult patients diagnosed at a tertiary academic hospital between 1990 and 2008. Patients' follow up ranged from 1 to 69 months (median 11 months). Surgery was attempted in all patients in whom complete resection in 15 patients (7%), subtotal resection in 77 patients (34%), partial resection in 73 patients (33%) and biopsy alone in 58 patients (26%) were done. In addition, we performed a literature review of PubMed to find out and analyze major related series. In all, we collected and analyzed the data of 33 major series including more than 11,000 patients with GBM.
RESULTS: There were 141 men and 82 women. The median progression free- and overall survival were 6 (95% CI=5.711-8.289) and 11 (95% CI=9.304-12.696) months respectively. In univariate analysis for overall survival, age (P=0.003), tumor size (P<0.013), performance status (P<0.001), the extent of surgical resection (P=0.009), dose of radiation (P<0.001), and adjuvant chemotherapy (P<0.001) were prognostic factors. However, in multivariate analysis, only radiation dose, extent of surgical resection, and adjuvant chemotherapy were independent prognostic factors for overall survival.
CONCLUSION: The prognosis of adult patients with GBM remains poor; however, complete surgical resection and adjuvant treatments improve progression-free and overall survival.
Copyright © 2012. Production and hosting by Elsevier B.V.

Entities:  

Mesh:

Year:  2012        PMID: 23499203     DOI: 10.1016/j.jnci.2012.11.001

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  29 in total

1.  Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.

Authors:  Maya Agarwal; Ryan T Nitta; Gordon Li
Journal:  J Mol Genet Med       Date:  2013-12-09

2.  Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.

Authors:  Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

3.  Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter?.

Authors:  Luiz Victor Maia Loureiro; Lucíola de Barros Pontes; Donato Callegaro-Filho; Ludmila de Oliveira Koch; Eduardo Weltman; Elivane da Silva Victor; Adrialdo José Santos; Lia Raquel Rodrigues Borges; Roberto Araújo Segreto; Suzana Maria Fleury Malheiros
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

Review 4.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

Review 5.  Rare case of radiation-induced trigeminal schwannoma occurring in a long-term glioblastoma multiforme survivor.

Authors:  Mina Al Shalchi; Shaila Hussain; Selvaraj Giridharan; Erminia Albanese
Journal:  BMJ Case Rep       Date:  2016-03-11

6.  Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme.

Authors:  Jia-Bin Wang; Feng-Hua Liu; Jian-Hang Chen; Hai-Tao Ge; Lu-Yan Mu; Hong-Bo Bao; Zhi-Guo Lin
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-06       Impact factor: 4.553

7.  Hypofractionated radiation therapy with temozolomide versus standard chemoradiation in patients with glioblastoma multiforme (GBM): A prospective, single institution experience.

Authors:  Amal Rayan; Samya Abdel-Kareem; Huda Hasan; Asmaa M Zahran; Doaa A Gamal
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-25

Review 8.  Molecular prognostic factors in glioblastoma: state of the art and future challenges.

Authors:  Ana Xavier-Magalhães; Meera Nandhabalan; Chris Jones; Bruno M Costa
Journal:  CNS Oncol       Date:  2013-11

Review 9.  Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment.

Authors:  George S Stoyanov; Deyan Dzhenkov; Peter Ghenev; Bogomil Iliev; Yavor Enchev; Anton B Tonchev
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

10.  Fluorescence-Guided versus Conventional Surgical Resection of High Grade Glioma: A Single-Centre, 7-Year, Comparative Effectiveness Study.

Authors:  Wei Ping Ng; Boon Seng Liew; Zamzuri Idris; Azmin Kass Rosman
Journal:  Malays J Med Sci       Date:  2017-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.